Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib following platinum-based chemotherapy extended progression-free survival in patients with metastatic urothelial carcinoma that harbors a biomarker for DNA repair deficiency, the results of a trial showed.
The final analysis of ATLANTIS, a phase 2, randomized, double-blind, placebo-controlled trial, showed a median progression-free survival (PFS) of 35.3 weeks in the rucaparib arm versus 15.1 weeks in the placebo